Filing Details

Accession Number:
0001209191-15-074185
Form Type:
4
Zero Holdings:
No
Publication Time:
2015-10-05 20:16:07
Reporting Period:
2015-10-01
Filing Date:
2015-10-05
Accepted Time:
2015-10-05 20:16:07
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
875320 Vertex Pharmaceuticals Inc / Ma VRTX Pharmaceutical Preparations (2834) 043039129
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1334365 Yuchun Lee C/O Vertex Pharmaceuticals Incorporated
50 Northern Avenue
Boston MA 02210
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2015-10-01 1,333 $57.27 1,541 No 4 M Direct
Common Stock Disposition 2015-10-01 200 $102.80 1,341 No 4 S Direct
Common Stock Disposition 2015-10-01 700 $104.79 641 No 4 S Direct
Common Stock Disposition 2015-10-01 225 $105.79 416 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2015-10-01 1,333 $0.00 1,333 $57.27
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
27,334 2022-09-13 No 4 M Direct
Footnotes
  1. Transaction made pursuant to Mr. Lee's company approved trading plan under Rule 10b5-1.
  2. Open market sales reported on this line occurred at a weighted average price of $102.80 (range $102.66 to $102.94).
  3. Mr. Lee undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
  4. Open market sales reported on this line occurred at a weighted average price of $104.79 (range $104.38 to $105.36).
  5. Open market sales reported on this line occurred at a weighted average price of $105.79 (range $105.74 to $105.85).
  6. The option vests in 16 quarterly installments from 09/14/2012.